Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.58 |
| ▸ | METAP2 | P50579 | 2/20 | 0.58 |
| ▸ | PLAU | P00749 | 1/20 | 0.53 |
| ▸ | NCF1 | P14598 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2484187 | 0.85 | METAP2 (0.55) | PARP1METAP2PLAUNCF1ALDH1A1 | |
| SCHEMBL4394002 | 0.84 | METAP2 (0.57) | METAP2PLAUNCF1ALDH1A1CYP1A2 | |
| SCHEMBL3212638 | 0.84 | METAP2 (0.57) | METAP2PLAUNCF1ALDH1A1CYP1A2 | |
| SCHEMBL9220073 | 0.82 | CCR1 (0.65) | METAP2PLAUNCF1ALDH1A1CYP1A2 | |
| SCHEMBL1160443 | 0.82 | METAP2 (0.51) | PARP1METAP2PLAUNCF1ALDH1A1 | |
| SCHEMBL5595463 | 0.81 | METAP2 (0.50) | PARP1METAP2PLAUNCF1ALDH1A1 | |
| SCHEMBL10425657 | 0.81 | PDE10A (0.50) | PARP1METAP2PLAUNCF1ALDH1A1 | |
| SCHEMBL6051279 | 0.81 | KCNH2 (0.56) | METAP2PLAUNCF1ALDH1A1CYP1A2 | |
| SCHEMBL2522559 | 0.81 | PLAU (0.58) | PARP1METAP2PLAUNCF1ALDH1A1 | |
| SCHEMBL4393939 | 0.81 | METAP2 (0.53) | METAP2PLAUNCF1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153791-B2 | substituted pyrimidine compoundssuch as 4-amino-6-(3-chloro-4-fluoro-phenylamino)-pyrimidine-5-carbaldehyde O-methyl oxime, used for treating, preventing or ameliorating a chronic or acute protein kinase mediated diseasea, disorders or conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-10 | — | — | US | claimed |
| WO-2009140215-A2 | METHOD FOR TREATING DRUG-RESISTANT BACTERIAL AND OTHER INFECTIONS WITH CLIOQUINOL, PHANQUINONE, AND RELATED COMPOUNDS | GERAGHTY, ERIN (US) | 2009-11-19 | — | — | WO | claimed |
| US-20080207673-A1 | Method for Treating Cancer, Coronary, Inflammatory and Macular Disease, Combining the Modulation of Zinc-and/or Copper Dependent Proteins | XILINAS MICHEL | 2008-08-28 | — | — | US | claimed |
| US-20070270425-A1 | SUBSTITUTED PYRIMIDINYL OXIME KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-22 | — | — | US | claimed |
| WO-2007081630-A2 | SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-19 | — | — | WO | claimed |
| EP-0412848-B1 | Quinoline derivatives, process for their preparation and their use as medicaments | ICI PLC (GB) | 1995-01-18 | — | — | EP | claimed |
| EP-0259687-A2 | Method for the preparation of pyridine-2,3-dicarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1988-03-16 | — | — | EP | claimed |
| CN-119307988-A | Antioxidant for methylsulfonic acid tinning and preparation method thereof | 宝山钢铁股份有限公司 | 2025-01-14 | — | — | CN | disclosed |
| EP-3318555-B1 | BIFUNCTIONAL CHELATING AGENTS | BWXT MEDICAL LTD (CA) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022136147-A1 | BISPIDINE DERIVATIVES AND THE USE THEREOF | HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF E.V. (DE) | 2022-06-30 | — | — | WO | disclosed |
| EP-4019051-A1 | BISPIDINE DERIVATIVES AND THE USE THEREOF | Helmholtz-Zentrum Dresden - Rossendorf e.V. (DE) | 2022-06-29 | — | — | EP | disclosed |
| WO-2022034916-A1 | POLYCYCLIC AROMATIC COMPOUND | 学校法人関西学院 | 2022-02-17 | — | — | WO | disclosed |
| US-11008290-B2 | Halogenated quinoline derivatives as antimicrobial agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-05-18 | — | — | US | disclosed |
| EP-1263720-A1 | AZETIDINE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2002-12-11 | — | — | EP | disclosed |
| EP-1149094-A2 | 4-(AMINOALKOXY)BENZOFURANS AS N-MYRISTOYLTRANSFERASE INHIBITORS | Basilea Pharmaceutica AG (CH) | 2001-10-31 | — | — | EP | disclosed |
| WO-2001064632-A1 | AZETIDINE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 2001-09-07 | — | — | WO | disclosed |
| WO-2000037464-A2 | 4-(AMINOALKOXY)BENZOFURANS AS N-MYRISTOYLTRANSFERASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2000-06-29 | — | — | WO | disclosed |
| EP-0098589-B1 | QUINAZOLINE DERIVATIVES WHICH ARE ACTIVE AGAINST COCCIDIOSIS | VETEM S.p.A. (IT) | 1987-12-09 | — | — | EP | disclosed |
| US-4632926-A | Quinazolinone derivatives which are active against coccidiosis | VETEM S.P.A. (IT) | 1986-12-30 | — | — | US | disclosed |
| EP-0098589-A1 | Quinazoline derivatives which are active against coccidiosis | VETEM S.p.A. (IT) | 1984-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270425-A1 | SUBSTITUTED PYRIMIDINYL OXIME KINASE INHIBITORS | MAP3K2, MAP3K1, MAP3K20 | PARP1 1786/4885METAP2 1490/4885PLAU 2894/4885 |
| US-11008290-B2 | Halogenated quinoline derivatives as antimicrobial agents | NDUFS5, NDUFS7, NDUFS3 | PARP1 1574/4885METAP2 2508/4885PLAU 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.